Tags : ALTA-1L

Takeda Reports Results of Alunbrig (brigatinib) in P-III ALTA-1L Study

Tuba Khan November 25, 2019

Shots: The P-III ALTA-1L study involves assessing of Alunbrig (180mg, qd for 7days lead in 90mg qd) vs Crizotinib (250mg, bid) in 275 patients with anaplastic lymphoma kinase-positive (ALK+) LA/ […]readmore

Tags : ALTA-1L

Takeda Reports Results of Alunbrig (brigatinib) in P-III ALTA-1L Study

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : ALTA-1L

Takeda Reports Results of Alunbrig (brigatinib) in P-III ALTA-1L Study

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company